Sangamo Therapeutics, Inc. (SGMO): history, ownership, mission, how it works & makes money

A Brief History of Sangamo Therapeutics, Inc. (SGMO)

Foundation and Early Years

Sangamo Therapeutics, Inc. was founded in 1995 by Edward Lanphier, with the aim of developing genomic therapies. The company focused initially on zinc finger protein technology, a novel approach for gene editing and modulation.

Initial Public Offering (IPO)

On November 16, 2013, Sangamo went public with an IPO, raising approximately $75 million. The initial offering price was set at $15 per share, with subsequent trading marking an important milestone for the company as it began to establish its presence in the biotechnology sector.

Advancements in Gene Therapy

In the following years, Sangamo expanded its focus on gene therapy applications, particularly in the fields of hemophilia, sickle cell disease, and beta-thalassemia. In 2020, the company announced a partnership with Pfizer to develop gene therapies for hemophilia B.

Financial Performance

As of Q3 2023, Sangamo Therapeutics reported total revenues of $18 million, a significant increase compared to $10 million in Q3 2022.

Product Pipeline and Collaborations

Sangamo Therapeutics has developed a robust pipeline of product candidates, including:

• SB-525, a gene therapy for hemophilia A
• ST-400, targeting beta-thalassemia
• ST-101 and ST-102, focused on immune tolerance

Recent Developments

In August 2023, Sangamo announced positive Phase 1/2 data from the ST-400 trial for beta-thalassemia, resulting in an increase in the company's stock price by 25% on the announcement day.

Market Capitalization

As of October 2023, Sangamo Therapeutics had a market capitalization of approximately $1.1 billion, indicating investor confidence in its long-term prospects.

Leadership Changes

In early 2022, Sangamo appointed a new CEO, which was noted as a strategic move to enhance its operational focus and innovation capabilities. The leadership change came after a series of pivotal clinical trial updates.

Stock Performance

As of October 2023, SGMO stock was trading at approximately $6.50 per share, reflecting a year-to-date increase of 30% amidst a favorable shift in investor sentiment related to gene therapy advancements.

A Who Owns Sangamo Therapeutics, Inc. (SGMO)

Company Overview

Sangamo Therapeutics, Inc. (SGMO) is a biotechnology company that focuses on genomic therapies. It specializes in developing innovative treatments for genetic diseases and conditions, including hemophilia, lysosomal storage disorders, and neurodegenerative diseases.

Ownership Structure

The ownership of Sangamo Therapeutics is distributed among various institutional investors, retail investors, and company insiders. As of the latest data, the ownership percentages are as follows:

Major Institutional Shareholders

Below are some of the major institutional shareholders that own significant stakes in Sangamo Therapeutics:

Insider Ownership

Insider ownership typically includes executives and board members. The following individuals are notable insiders:

Stock Performance and Market Capitalization

Sangamo Therapeutics has had varied performance on the stock market. As of October 2023, the stock price and market capitalization are:

Recent Shareholder Changes

The following table illustrates recent changes in significant shareholders:

Conclusion on Ownership Trends

Ownership trends at Sangamo Therapeutics indicate significant institutional interest, which often correlates with confidence in the company’s potential. The data reflects the current market sentiment regarding Sangamo's approaches to genomic therapies.

Sangamo Therapeutics, Inc. (SGMO) Mission Statement

Core Mission

Sangamo Therapeutics, Inc. aims to leverage its innovative gene therapy and gene editing technologies to transform the lives of patients with serious diseases. The company focuses on developing genomic therapies in a variety of therapeutic areas, including neurological diseases, hemophilia, and other genetic disorders.

Strategic Objectives

• Patient-Centric Approach: Dedication to addressing unmet medical needs.
• Innovative Technology: Utilizing a platform that includes zinc finger protein (ZFP) technology.
• Collaboration: Partnering with leading pharmaceutical companies to enhance research and development.

Recent Financial Performance

In the most recent fiscal year, Sangamo Therapeutics reported revenues of approximately $43.4 million, a significant increase from $29.9 million in the previous year. The financial performance can be broken down as follows:

Research and Development Focus

Sangamo is committed to advancing its R&D pipeline, with several key programs currently in various stages of clinical trials. Notable breakthroughs include:

• ST-920 for Fabry Disease – Phase 1/2 trial ongoing.
• SB-525 for Hemophilia A – partnerships with Pfizer.
• Gene therapy for CNS Disorders – exploring new indications.

Market Position and Collaborations

Sangamo holds strategic collaborations with major pharmaceutical companies, enhancing its market presence:

Long-Term Vision

The vision of Sangamo Therapeutics is to become a leader in the field of genomic medicine, aiming to develop cures rather than treatments, thereby potentially transforming the healthcare landscape for individuals dealing with severe genetic diseases.

Community and Advocacy

Sangamo is actively involved in patient advocacy and community outreach, focusing on:

• Raising Awareness: Engaging in educational initiatives about genetic disorders.
• Supporting Patients: Providing resources and support networks for affected individuals.

How Sangamo Therapeutics, Inc. (SGMO) Works

Corporate Overview

Sangamo Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on genomic therapies. The company was founded in 1995 and is headquartered in Richmond, California. As of October 2023, Sangamo's market capitalization was approximately $363 million.

Business Model

Sangamo employs a unique business model centered on the development of innovative gene therapies using its proprietary zinc finger protein (ZFP) technology. This technology enables precise modifications of genes in a patient's genome.

Key components of the business model include:

• Targeting genetic diseases and disorders.
• Collaboration with large pharmaceutical companies for drug development.
• Focus on advancing clinical-stage programs to increase shareholder value.

Financial Performance

For the fiscal year 2022, Sangamo Therapeutics reported total revenue of $51.4 million, an increase from $41.3 million in 2021. The breakdown of revenue sources in 2022 is as follows:

Research and Development (R&D)

In 2022, Sangamo invested approximately $127 million in research and development activities, compared to $113 million in the previous year. Major R&D programs include:

• Gene therapy programs for hemophilia A and B.
• Therapies for neurodegenerative diseases.
• Cell therapy approaches for oncology.

Clinical Trials

Sangamo has several ongoing clinical trials, including:

• SB-525 for hemophilia A – Phase 3
• ST-400 for beta-thalassemia – Phase 1/2
• ENGAGE trial for Alzheimer’s disease – Phase 1

As of mid-2023, clinical updates indicated the following:

Collaborations and Partnerships

Sangamo has established several collaborations to advance its research and product pipeline. Notably:

• Collaboration with Pfizer for hemophilia A therapies.
• Partnership with Janssen Pharmaceuticals for gene editing programs.
• Collaboration with Novartis for cell therapy research.

Stock Performance

The stock performance of Sangamo Therapeutics has shown volatility over the years. As of October 2023, the stock price was approximately $3.50 per share, up from $2.80 at the beginning of the year. The company's 52-week trading range has been between $2.50 and $5.10.

Intellectual Property

Sangamo holds a robust portfolio of over 900 patents related to its ZFP technology and applications in gene editing. The company continues to focus on expanding its intellectual property rights globally.

How Sangamo Therapeutics, Inc. (SGMO) Makes Money

Revenue Streams

Sangamo Therapeutics, Inc. generates income through various channels, including collaborations, licensing agreements, and clinical product sales.

Collaborations and Partnerships

Collaborative agreements are a significant part of Sangamo’s business model. As of 2023, Sangamo has established partnerships with multiple companies, such as:

• Pfizer: In December 2020, a collaboration worth up to $425 million was announced.
• Biogen: The partnership is valued at up to $150 million.
• Novartis: The licensing agreement includes up to $150 million in upfront and milestone payments.

Licensing Agreements

Sangamo earns revenue from licensing its proprietary technologies for gene therapies. In 2022, the company recognized $14.4 million from licensing revenue.

Clinical Development Programs

The company is focused on developing innovative therapies for genetic diseases, with several ongoing clinical trials:

• SZ-401: Aids in the treatment of Hemophilia A.
• ST-400: Targets β-thalassemia.
• SB-913: Aimed at treating Mucopolysaccharidosis Type II.

Financial Performance

As of the end of Q2 2023, Sangamo reported:

Market Potential

The gene therapy market is projected to grow significantly. According to a market research report, it is expected to reach approximately $30 billion by 2030.

Stock Performance and Financing

Sangamo’s stock (SGMO) has experienced fluctuations. As of October 2023, the stock price was approximately $3.25. The company has been actively seeking to raise capital, including a successful public offering raising $50 million in 2022.

Intellectual Property

Sangamo holds various patents that protect its technologies, which contributes to its competitive advantage and revenue generation potential.

Future Outlook

Future revenues are anticipated through progressing clinical trials and expanding collaborations. Analysts forecast potential revenue increases as products move closer to commercialization.